JADPRO Live 2017 Activities
Updates in Heme Malignancy Side Effects
Myeloproliferative Neoplasms Updates
Knowledge Center: Oral Oncolytics
Narratives: HER2-Positive Breast Cancer
What are the biosimilars with current or pending approval from the FDA?
Christopher J. Campen, PharmD, BCOP
Related article in JADPRO Vol 8, No 7, Nov/Dec 2017 issue
Copyright © 2010-2018 Harborside Press, LLC All rights reserved.
Bot trap - Don't go here
to learn more.